Neurology, Behavioral Neurology

• 

  People

  • Primary Appointments

    • Burke, James Robert, Professor of Neurology
    • Chiba-Falek, Ornit, Professor in Neurology
    • Colton, Carol Anne, Professor in Neurology
    • Davis, Simon Wilton, Assistant Professor in Neurology
    • Gottschalk, William Kirby, Assistant Professor in Neurology
    • La Spada, Albert R, Adjunct Professor in the Department of Neurology
    • Liu, Andrew John, Assistant Professor of Neurology
    • Lutz, Michael William, Associate Professor in Neurology
    • Strittmatter, Warren James, Professor Emeritus of Neurology
    • Vitek, Michael P., Adjunct Associate Professor in Neurology

  • Secondary Appointments

    • Cook, Sarah, Assistant Professor in Neurology
    • Farrer, Thomas J., Assistant Professor in Neurology
    • Fekrat, Sharon, Professor in Neurology
    • Johnson, Kim G, Assistant Professor in Neurology
    • Koltai, Deborah, Associate Professor in Neurology
    • Parker, Daniel Christopher, Assistant Professor in Neurology
    • Plassman, Brenda Lee, Professor of Neurology
    • Wang, Shih-Hsiu, Assistant Professor in Neurology
    • Welsh-Bohmer, Kathleen Anne, Professor in Neurology
    • West, Andrew Bradley, Professor in the Department of Neurology

  • Joint Appointments

    • Badea, Alexandra, Associate Professor in the Department of Neurology

  • Non-Faculty Positions

    • Gonzalez-Hunt, Claudia, Research Associate, Senior
• 

  Administers Grant

  • A 72-Week, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease (AD) (Stage 3 AD) to Evaluate the Effect on Cognitive and Functional Impairment, Safety, and Tolerabilit
  • A Blinded Longterm Ext Study to Eval the Safety and Efficacy of Pioglitazone (AD-4833 Sust Release 0.8 mg daily) to Slow the Progress of Cog Decline in Subj Who Have completed the AD4833/TOMM40_301 Study w/ Diag of Mild Cog Impair due to Alz Disease.
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
  • A Novel Animal Model of Late Onset Alzheimer's Disease
  • A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 52 Week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease
  • A Phase III Clinical Trial to Study the Efficacy & Safety of MK-8931 (SCH900931) in subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)
  • A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer's Disease
  • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer¿s Disease o
  • A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
  • A novel gene-therapy strategy for Parkinson's disease (PD): Epigenome editing mediated-regulation of SNCA expression
  • A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)
  • A randomized, double-blind, placebo-controlled, two cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease
  • ADCC Genomic Medical Approach to MCI and Dementia
  • AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects W
  • Adaptive Neuromodulation of Working Memory Networks in Aging and Dementia
  • Admin Suppl - Novel therapeutics in Parkinson's disease: Identification of alpha-synuclein binding peptides by screening
  • Advanced Glycosylation Endproducts And Ad Amyloidosis
  • Alzheimer'S Disease Research Center
  • Alzheimer'S Disease Research Center
  • Alzheimer'S Disease Research Center
  • Alzheimer'S Disease Research Center
  • Alzheimer's Disease Research Center
  • An Extension Study of ABBV-8E12 in Early Alzheimer's Disease
  • Animal Model Of Alzheimer'S Disease Pathology
  • Animal model of Alzheimers Disease Pathology
  • ApoE, Alzheimers and Aging: discover the tripleA in iPSC-derived models
  • Apolipoprotein E/Tau Interactions In Alzheimer'S Disease
  • Apolipoprotein E/Tau Interactions In Alzheimers Disease
  • Arly Genes And Kindling Development
  • Ataxia Investigators Meeting 8: Leveraging Therapeutic Opportunity into Novel Treatment Paradigms
  • Ataxin-7 oligonucleotide knock-down to treat SCA7 retinal and cerebellar disease
  • Bryan ADRC Brain Bank
  • Center For Genetic Studies In Neurological Disorders
  • Cognitive Endophenotypes for Genetic Studies of Alzheimer's Disease
  • Combination anti-amyloid therapy for preclinical Alzheimer's disease
  • Consortium To Establish A Registry For Alzheimer'S Disease
  • Creating a mouse model for neurodegenerative disease by "humanizing" NOS2
  • Deciphering the regulation of gene expression in the etiology of LOAD
  • Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy
  • Dysregulation of the neurovascular unit in Alzheimer's Disease
  • Early Genes And Kindling Development
  • Enhanced skeletal muscle proteostasis as a determinant of CNS protein quality control and neural function in the aging brain
  • Epidemiology of Dementia in Cache County, Utah
  • Epidemiology of Dementia in Cache County, Utah (Bridge-Funding Request)
  • Evaluation of PPAR-delta/gamma Agonist Therapy as a Novel Treatment Paradigm for ALS
  • Gender and APOE genotype interact to alter immune regulated metabolism in AD
  • Gender and APOE genotype interact to alter immune regulated metabolism in AD
  • Genetic Analysis Methods For Medical Researchers
  • Genetic Analysis Methods For Medical Researchers
  • Genetic Studies In Neurological Disorders
  • Genetics studies in neurological disorders(Suppl to NS26630)
  • Genomic Screen To Identify Alzheimer Disease Genes
  • Genomic Screen To Identify Alzheimer'S Disease Genes
  • Hepara sulfate proteoglycan in Alzheimer's disease
  • Humanized Animal Model Of Oxyradical Production
  • Identification of Genetic Factors that Impact the Risk of Alzheimer's Disease with Age
  • Immune Responsiveness, APOE/Gender in Neurodegeneration
  • Immune regulated amino acid pathways in Alzheimer's Disease
  • Immune-based nutrient deprivation and neurodegenerative disease
  • Immunosuppression in humans with AD
  • Increasing sensitivity to enviromental stress by humanizing NOS2 in mouse
  • International Workshop In Human Chromosome 9
  • International Workshop On Human Chromosome 9
  • International Workshop On Human Chromosome 9
  • Lewy body neuropathologies and SNCA gene: variants expression and splicing
  • Lewy body neuropathologies and SNCA gene: variants expression and splicing
  • Manipulation of polyglutamine-protein interactions
  • Mapping And Gene Expression In Autism Region On Ch 15
  • Mechanistic link between LRRK2, alpha-synuclein and lysosomal function in PD
  • Molecular genetic regulation of autophagy in health and neurodegenerative disease
  • NINDS Administrative supplement for FDA-approved compound screens for neurodegeneration
  • Novel Orally Available Prodrugs for Alzheimer's Disease
  • Onset of immune pathlogy in AD
  • Open-Label Extension of Studies ATH-1017-0201 and ATH-1017-0202 in Subjects with Mild to Moderate Alzheimer¿s Disease
  • Regulation of microglial activation
  • Regulation of microglial function by ApoE
  • Regulation of neuronal NO by apolipoprotein E
  • Role of the TOMM40 poly-T variant in the pathogenesis of Alzheimer's disease
  • SBMA motor neuron degeneration: From cellular and molecular basis to therapy
  • SCA7 neurodegeneration: Molecular epigenetic basis and therapy
  • Same
  • Sex-dependent genetic landscape of late-onset Alzheimer's disease
  • Shared genetic, epigenetic, and transcriptomic profiles between AD and PTSD: molecular insights into the heterogeneity of neuropsychiatric symptoms in Alzheimers Disease
  • Slowing arginine utilization by inhibiting arginase and ornithine decarboxylase with DFMO
  • Social adversities, epigenetics, and the obesity epidemic
  • Studies In Autism And Related Disorders
  • Synuclein-One Study
  • The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease
  • The PPAR-delta pathway in neural function and Huntington's disease neuropathology
  • The amyloid cascade in a novel mouse model of Alzheimer's disease
  • Therapeutic Effects of Exercise in Adults with Amnestic Mild Cognitive Impairment ("EXERT")
  • Triple transgenic model of Alzheimer's Disease
  • UNIVERSITY HOSPITALS HARRINGTON DISCOVERY INSTITUTE ADDF HARRINGTON SCHOLAR GRANT AGREEMENT
  • Untangling the diversity in the genetic architecture of late-onset Alzheimer's disease using single cell multi-omics
  • VRFCAT Content Validity
  • same
  • same
  • same

Add data to my Website